Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Buck Institute For Research On Aging patents


Recent patent applications related to Buck Institute For Research On Aging. Buck Institute For Research On Aging is listed as an Agent/Assignee. Note: Buck Institute For Research On Aging may have other listings under different names/spellings. We're not affiliated with Buck Institute For Research On Aging, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "B" | Buck Institute For Research On Aging-related inventors


Nucleic acid construct with a p16 promoter that causes a prodrug converting enzyme to be expressed specifically in senescent cells

This disclosure provides non-human animal models for age-related disorders and age-sensitive traits, particularly those caused by senescence-inducing stimuli, wherein the models comprise transgenes selectively expressed by senescent cells. The disclosure further provides methods for identifying therapeutic agents effective for treating or preventing age-related disorders and age-sensitive traits using the animal models, therapeutic agents identified using such methods, pharmaceutical compositions comprising the identified therapeutic agents, and methods of treating or preventing age-related disorders and age-sensitive traits.. ... Buck Institute For Research On Aging

Modulators of alpha-dicarbonyl detoxification and their use for the treatment of diabetic pathologies

In various embodiments compositions and methods are provided for ameliorating a pathology characterized by elevated α-dicarbonyl compounds or prophylactically slowing or stopping the onset of said pathology in a mammal. In certain embodiments the method comprises administering to the mammal an agent that activates trpa1 in an amount sufficient to activate trpa1, and/or to ameliorate one or more symptoms of the pathology (e.g., diabetes or a complication thereof), and/or to slow or stop the onset of the pathology, and/or to lower the level of α-dicarbonyl compounds in the mammal.. ... Buck Institute For Research On Aging

Use of a heterocyclic bcl-xl inhibitor and related analogs for removing senescent cells in the treatment of eye diseases and other age-related conditions

A library of heterocyclic compounds has been screened to identify particular compounds that have high inhibitory capacity for the bcl family of regulatory proteins. Compounds identified as bcl antagonists have been further screened to select pharmaceutical agents with both high potency and high specificity for eliminating senescent cells in comparison with replicative or quiescent cells of the same tissue type. ... Buck Institute For Research On Aging

Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications

In various embodiments a cancer treatment method is provided based on inhibition of proline catabolism. When combined with p53 restoration therapy and/or inhibition of glutaminase, the inhibition of proline catabolism results in a “synthetic lethal” and synergistic anticancer response. ... Buck Institute For Research On Aging

Downregulation of sine/alu retrotransposon transcription to induce or restore proliferative capacity and/or pluripotency to a stem cell

In certain embodiments methods are provided for inducing and/or restoring and/or maintaining a non-senescent phenotype, or aspects thereof (e.g., proliferative capacity and/or pluripotency) in a mammalian cell. The methods typically involve reducing the level or activity of sine/alu retrotransposon transcripts in the cell in an amount sufficient to induce or restore proliferative capacity and/or pluripotency to said mammalian cell.. ... Buck Institute For Research On Aging

Methods and compositions for modulating the imune system

Methods and compositions for cell therapy using immune modulating peptides comprising a manf family protein, or fragment thereof, as an adjuvant to improve replacement cell viability and integration. The methods and compositions can be used in the treatment of a variety of diseases and disorders, including retinal diseases.. ... Buck Institute For Research On Aging

Use of a heterocyclic bcl-2 inhibitor for removing senescent cells and treating senescence-associated conditions

Disclosed herein are compounds that are effective for treatment of various disease states. Dosing includes both single administration and regimens of cycling dosages.. ... Buck Institute For Research On Aging

Apoe4-targeted theraputics that increase sirt1

A link between apoe4 allele and sirtuins expression level is identified that is believed to be associated with elevated risk for the promotion of processing of amyloid precursor protein (app) by the non-amyloidogenic pathway in a mammal leading to elevated risk for alzheimer's disease. Compounds are identified that upregulate sirtuins (e.g., sirt1) expression levels and appear to be useful in the treatment and/or prophylaxis of mci and/or alzheimer's disease.. ... Buck Institute For Research On Aging

Methods for improving medical therapies

Methods are provided herein for enhancing the effectiveness of medical therapies by administering agents that suppress a biological damage response that is inducible by the medical therapy administered to a subject. In certain embodiments, a method is provided for administering an anti-senescent cell agent that suppresses a biological response comprising cellular senescence that is induced by the medical therapy.. ... Buck Institute For Research On Aging

Lipoic acid and derivatives thereof for the treatment of cystinuria

In various embodiments methods and composition are provided for the treatment and/or prophylaxis of cystinuria. In certain embodiments the methods involve administering to a mammal in need thereof (e.g., identified as at risk for, or having cystinuria) an effective amount of lipoic acid and/or one or more lipoic acid derivatives.. ... Buck Institute For Research On Aging

Animal models of age-related disorders and age-sensitive traits associated with senescence-inducing stimuli and uses thereof

This disclosure provides non-human animal models for age-related disorders and age-sensitive traits, particularly those caused by senescence-inducing stimuli, wherein the models comprise transgenes selectively expressed by senescent cells. The disclosure further provides methods for identifying therapeutic agents effective for treating or preventing age-related disorders and age-sensitive traits using the animal models, therapeutic agents identified using such methods, pharmaceutical compositions comprising the identified therapeutic agents, and methods of treating or preventing age-related disorders and age-sensitive traits.. ... Buck Institute For Research On Aging








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Buck Institute For Research On Aging in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Buck Institute For Research On Aging with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###